This finding demonstrated for the first time that CD36 can act as a positive regulator of tumor angiogenesis in contrast to previous results where CD36 inhibited tumor angiogenesis and challenges therapies to counteract tumor angiogenesis via the CD36 pathway. This evidence concerns the gene CD36 and neoplasm.